World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
40602
World Ranking
6550
National Ranking
3478

Overview

Neil E. Kay is affiliated with the Mayo Clinic in the United States. Their research predominantly centers on medicine, with a significant focus on genetics, pathology and forensic medicine, immunology, oncology, and molecular biology. Within these fields, their work extensively addresses chronic lymphocytic leukemia research, lymphoma diagnosis and treatment, immunodeficiency and autoimmune disorders, CAR-T cell therapy research, advanced breast cancer therapies, acute lymphoblastic leukemia research, and gastrointestinal tumor research and treatment.

The scientist has contributed to numerous publications, with a strong presence in high-impact journals. Frequent publication venues include Blood, Cancer Research, Leukemia, Blood Cancer Journal, and Journal of Clinical Oncology.

Recent research papers authored or co-authored by Neil E. Kay include:

  • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial, 2021, Journal of Clinical Oncology
  • Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial, 2022, Blood
  • Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma, 2022, Blood
  • Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia, 2020, Molecular Therapy
  • Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia, 2020, Leukemia Research

The scientist collaborates frequently with several co-authors, such as Sameer A. Parikh, Susan L. Slager, Kari G. Rabe, Saad S. Kenderian, and Esteban Braggio, reflecting teamwork on multiple projects across their research career.

Neil E. Kay's main fields of study encompass Medicine with over 400 publications, further branching into subfields with considerable research output in Genetics (172 publications), Pathology and Forensic Medicine (81 publications), Immunology (63 publications), Oncology (45 publications), and Molecular Biology (28 publications).

The main topics that appear consistently across their work include:

  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders
  • CAR-T cell therapy research
  • Advanced Breast Cancer Therapies
  • Acute Lymphoblastic Leukemia research
  • Gastrointestinal Tumor Research and Treatment

Best Publications

  • National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment

    Bruce D. Cheson;John M. Bennett;Michael Grever;Neil Kay

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

    Laura Z. Rassenti;Lang Huynh;Tracy L. Toy;Liguang Chen

  • Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Xin V. Wang;Neil E. Kay;Curtis A. Hanson

  • Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute-sponsored working group

    Bruce D. Cheson;John M. Bennett;Kanti R. Rai;Michael R. Grever

  • GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

    Rosalie M. Sterner;Reona Sakemura;Michelle J. Cox;Nan Yang

  • Diagnostic criteria for monoclonal B-cell lymphocytosis.

    Gerald E. Marti;Andy C. Rawstron;Paolo Ghia;Peter Hillmen

  • Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

    Antonina V. Kurtova;Kumudha Balakrishnan;Rong Chen;Wei Ding

  • Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

    Wei Ding;Betsy R. LaPlant;Timothy G. Call;Sameer A. Parikh

  • Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

    Neil E. Kay;Susan M. Geyer;Timothy G. Call;Tait D. Shanafelt

  • Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia

    Laura Z. Rassenti;Sonia Jain;Michael J. Keating;William G. Wierda

  • Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

    Rafael Fonseca;Emily A. Blood;Emily A. Blood;Martin M. Oken;Martin M. Oken;Robert A. Kyle;Robert A. Kyle

  • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.

    John C Byrd;Peter Hillmen;Paolo Ghia;Arnon P Kater

  • Association of a microRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-cell Chronic Lymphocytic Leukemia

    Muller Fabbri;Arianna Bottoni;Masayoshi Shimizu;Riccardo Spizzo

  • Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

    Natali Pflug;Jasmin Bahlo;Tait D. Shanafelt;Barbara F. Eichhorst

  • Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Thomas E. Witzig;Stephanie R. Fink;Robert B. Jenkins

  • Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL.

    Tait D. Shanafelt;Susan M. Geyer;Neil E. Kay

  • Chronic Lymphocytic Leukemia

    Neil E. Kay;Terry J. Hamblin;Diane F. Jelinek;Gordon W. Dewald

  • Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia

    Gordon W. Dewald;Stephanie R. Brockman;Sarah F. Paternoster;Nancy D. Bone

  • VEGF Receptor Phosphorylation Status and Apoptosis is Modulated by a Green Tea Component, Epigallocatechin-3-gallate (EGCG) in B cell Chronic Lymphocytic Leukemia

    Yean K. Lee;Nancy D. Bone;Ann K. Strege;Tait D. Shanafelt

Frequent Co-Authors

Tait D. Shanafelt
Tait D. Shanafelt Stanford University
Susan L. Slager
Susan L. Slager Mayo Clinic
Diane F. Jelinek
Diane F. Jelinek Mayo Clinic
Kari G. Rabe
Kari G. Rabe Mayo Clinic
Curtis A. Hanson
Curtis A. Hanson Mayo Clinic
James R. Cerhan
James R. Cerhan Mayo Clinic
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Thomas E. Witzig
Thomas E. Witzig Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The landscape of medical education is evolving, with more students exploring online degrees to advance their healthcare careers. For those interested in healthcare administration, pursuing a cahme accredited online mha can open doors to leadership roles in hospitals, clinics, and public health organizations.

Registered nurses looking to further their credentials may consider an rn to bsn online without clinicals program. These flexible pathways are designed for working professionals and may minimize time away from work.

For nurses aiming for the highest level of practice, programs like the shortest msn to dnp program provide a fast track to a Doctor of Nursing Practice degree. Additionally, some online dnp programs without clinicals offer a streamlined experience for experienced practitioners seeking leadership or academic roles.

With these diverse online routes, you can align your medical education with your career goals and lifestyle, making advanced healthcare degrees more accessible than ever.

Best Scientists Citing Neil E. Kay

Trending Scientists